Claims
- 1. A method for modulating angiogenesis in a target tissue in a subject, the method comprising a non-naturally occurring step of modulating the level of differentiation of hemangioblasts to blood vessel cells in the subject.
- 2. The method of claim 1, wherein the step of modulating the level of differentiation of hemangioblasts to blood vessel cells in the subject comprises increasing or decreasing the number of hemangioblasts in the subject.
- 3. The method of claim 2, wherein the step of modulating the level of differentiation of hemangioblasts to blood vessel cells in the subject comprises increasing the number of hemangioblasts in the subject.
- 4. The method of claim 3, wherein the step of increasing the number of hemangioblasts in the subject is performed by administering hemangioblasts to the subject.
- 5. The method of claim 4, wherein hemangioblasts administered to the subject are derived from cells that were removed from the subject.
- 6. The method of claim 5, wherein the cells that were removed from the subject were expanded in vitro prior to being administered to the subject.
- 7. The method of claim 4, wherein hemangioblasts administered to the subject are derived from cells from a donor other than the subject.
- 8. The method of claim 7, wherein the cells from the donor were expanded in vitro prior to being administered to the subject.
- 9. The method of claim 2, wherein the step of modulating the level of differentiation of hemangioblasts to blood vessel cells in the subject comprises decreasing the number of hemangioblasts in the subject.
- 10. The method of claim 9, wherein the step of decreasing the number of hemangioblasts in the subject comprises administering to the subject an agent that depletes hemangioblasts.
- 11. The method of claim 10, wherein the agent is an antibody that specifically binds a molecule present on the surface of hemangioblasts.
- 12. The method of claim 1, wherein the step of modulating the level of differentiation of hemangioblasts to blood vessel cells in the subject comprises increasing or decreasing the recruitment of hemangioblasts from bone marrow to a non-bone marrow compartment.
- 13. The method of claim 12, wherein the step of modulating the level of differentiation of hemangioblasts to blood vessel cells in the subject comprises increasing the recruitment of hemangioblasts from bone marrow to a non-bone marrow compartment.
- 14. The method of claim 12, wherein the step of modulating the level of differentiation of hemangioblasts to blood vessel cells in the subject comprises decreasing the recruitment of hemangioblasts from bone marrow to a non-bone marrow compartment.
- 15. A method for decreasing blood vessel formation in a subject, the method comprising the step of administering to the subject an agent that blocks the activity of SDF-1.
- 16. The method of claim 15, wherein the agent is an antibody that specifically binds SDF-1.
- 17. The method of claim 15, wherein the agent is administered to an eye of the subject.
- 18. The method of claim 16, wherein the agent is administered to an eye of the subject.
- 19. A hemangioblast isolated from adult bone marrow.
- 20. The hemangioblast of claim 19, wherein the adult bone marrow is mammalian bone marrow.
- 21. A method for isolating an hemangioblast from the bone marrow of an adult animal, the method comprising the steps of:
(a) isolating bone marrow from the animal, wherein the bone marrow comprises at least one hemangioblast and at least one non-hemangioblast cell; (b) separating the at least one hemangioblast and the at least one non-hemangioblast cell; and (c) collecting the at least one hemangioblast.
- 22. The method of claim 21, wherein the step (b) of separating the at least one hemangioblast and the at least one non-hemangioblast cell comprises contacting the bone marrow with an agent that specifically binds the at least one hemangioblast but not the at least one non-hemangioblast cell.
- 23. The method of claim 21, wherein the step (b) of separating the at least one hemangioblast and the at least one non-hemangioblast cell comprises contacting the bone marrow with an agent that specifically binds the at least one non-hemangioblast cell but not the at least one hemangioblast.
- 24. The method of claim 22, wherein the agent is an antibody.
- 25. The method of claim 23, wherein the agent is an antibody.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims the priority of U.S. provisional patent application serial No. 60/367,078, filed Mar. 21, 2002; U.S. provisional patent application serial No. 60/429,744 filed Nov. 27, 2002; and U.S. provisional patent application serial No. 60/448,691 filed Feb. 19, 2003.
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] The invention was made with United States government support under grant number HL70738 awarded by the National Institutes of Health. The United States government may have certain rights in the invention.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60367078 |
Mar 2002 |
US |
|
60429744 |
Nov 2002 |
US |
|
60448691 |
Feb 2003 |
US |